Has the emergence of community-associated methicillin-resistant staphylococcus aureus increased trimethoprim-sulfamethoxazole use and resistance?: A 10-year time series analysis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5655-5660

  Wood, Jameson B ^a   Smith, Donald B ^a   Baker, Errol H ^a   Brecher, Stephen M ^a   Gupta, Kalpana ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OUTPATIENT DEPARTMENT; PRESCRIPTION; PRIORITY JOURNAL; PROTEUS MIRABILIS; STREPTOCOCCUS PNEUMONIAE; TIME SERIES ANALYSIS;

ADULT; ANTI-BACTERIAL AGENTS; BOSTON; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; SKIN; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84868019910     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01011-12     Document Type: Article

References (35)

1. Bean DC, Livermore DM, Hall LM. 2009. Plasmids imparting sulfon-amide resistance in Escherichia coli: implications for persistence. Antimicrob. Agents Chemother. 53:1088-1093.
2. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. 2011. Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin. Infect. Dis. 52:99-114.
3. Colgan R, Johnson JR, Kuskowski M, Gupta K. 2008. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrob. Agents Chemother. 52:846-851.
4. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. 2010. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 340:c2096.
5. Cunha BA. 2012. Prophylaxis for recurrent urinary tract infections: nitrofurantoin, not trimethoprim-sulfamethoxazole or cranberry juice. Arch. Intern. Med. 172:82-83.
6. Enne VI, Livermore DM, Stephens P, Hall LM. 2001. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357:1325-1328.
7. Fridkin SK, et al. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352:1436-1444.
8. Gaynes RP. 2010. Preserving the effectiveness of antibiotics. JAMA 303: 2293-2294.
9. Goldberg E, Bishara J. 2012. Contemporary unconventional clinical use of co-trimoxazole. Clin. Microbiol. Infect. 18:8-17.
10. Gonzales R, Steiner JF, Lum A, Barrett PH, Jr. 1999. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 281:1512-1519.
11. Green H, Paul M, Vidal L, Leibovici L. 2007. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst. Rev:CD005590.
12. Grimwade K, and Swingler. 2003. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database Syst. Rev: CD003108.
13. Gupta K, Hooton TM, Miller L. 2011. Managing uncomplicated urinary tract infection: making sense out of resistance data. Clin. Infect. Dis. 53: 1041-1042.
14. Gupta K, et al. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52:e103-120.
15. Gupta K, Macintyre A, Vanasse G, Dembry LM. 2007. Trends in prescribing beta-lactam antibiotics for treatment of community-associated methicillin-resistant Staphylococcus aureus infections. J. Clin. Microbiol. 45:3930-3934.
16. Gupta K, Scholes D, Stamm WE. 1999. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 281:736-738.
17. Hughes JM. 2011. Preserving the lifesaving power of antimicrobial agents. JAMA 305:1027-1028.
18. King MD, et al. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144:309-317.
19. Korbila IP, Manta KG, Siempos II, Dimopoulos G, Falagas ME. 2009. Penicillins versus trimethoprim-based regimens for acute bacterial exacerbations of chronic bronchitis: meta-analysis of randomized controlled trials. Can. Family Physician 55:60-67.
20. Levy SB. 2008. Genome size and antibiotic resistance. Antimicrob. Agents Chemother. 52:2696.
21. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292.
22. Martin JN, et al. 1999. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J. Infect. Dis. 180:1809-1818.
23. McKnight SD, McKean JW, Huitema BE. 2000. A double bootstrap method to analyze linear models with autoregressive error terms. Psychol. Methods 5:87-101.
24. Paterson DL. 2004. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(Suppl 4):S341-S345.
25. Perencevich EN, Lautenbach E. 2011. Infection prevention and comparative effectiveness research. JAMA 305:1482-1483.
26. Projan SJ. 2007. (Genome) size matters. Antimicrob. Agents Chemother. 51:1133-1134.
27. Sanchez GV, Master RN, Bordon J. 2011. Trimethoprim-sulfamethoxazole may no longer be acceptable for the treatment of acute uncomplicated cystitis in the United States. Clin. Infect. Dis. 53:316-317.
28. Shardell M, et al. 2007. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin. Infect. Dis. 45:901-907.
29. Sibanda EL, Weller IV, Hakim JG, Cowan FM. 2011. Does trim-ethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin. Infect. Dis. 52:1184-1194.
30. Stevens DL, et al. 2005. Practice guidelines for the diagnosis and management ofskin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406.
31. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. 2008. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole-and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin. Infect. Dis. 47:1150-1158.
32. Tosh PK, McDonald LC. 2012. Infection control in the multidrug-resistant era: tending the human microbiome. Clin. Infect. Dis. 54:707-713.
33. van der Veen EL, et al. 2009. Effect of long-term trimethoprim/ sulfamethoxazole treatment on resistance and integron prevalence in the intestinal flora: a randomized, double-blind, placebo-controlled trial in children. J. Antimicrob. Chemother. 63:1011-1016.
34. Vernaz N, et al. 2011. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J. Antimicrob. Chemother. 66: 928-935.
35. Wagenlehner FM, et al. 2011. Uncomplicated urinary tract infections. Dtsch. Arztebl. Int. 108:415-423.